Opthea (NASDAQ:OPT – Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Opthea to post earnings of ($0.43) per share for the quarter.
Opthea Price Performance
Shares of OPT opened at $4.94 on Tuesday. Opthea has a twelve month low of $1.79 and a twelve month high of $6.30. The firm has a 50 day moving average of $4.40 and a 200 day moving average of $3.93.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the company. Canaccord Genuity Group upgraded Opthea to a “strong-buy” rating in a research note on Tuesday, December 17th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Opthea in a report on Wednesday, January 29th.
About Opthea
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Featured Articles
- Five stocks we like better than Opthea
- What Is WallStreetBets and What Stocks Are They Targeting?
- Finding Hidden Gems: Unconventional Penny Stock Investing
- Retail Stocks Investing, Explained
- Price Targets on NVIDIA Rise in Front of Earnings
- Consumer Discretionary Stocks Explained
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
